Immunohistochemical study of claudin 18 involvement in intestinal differentiation during the progression of intraductal papillary mucinous neoplasm

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 2995-3003

  Sanada, Yuichi ^a   Hirose, Oshinobu ^a   Osada, Shinji ^a   Tanaka, Yoshihiro ^a   Takahashi, Takao ^a   Yamaguchi, Kazuya ^a   Yoshida, Kazuhiro ^a  

^a Graduate School of Medicine   (Japan)

Author keywords

Claudin 18; Gli 1; Intraductal papillary mucinous neoplasm; p53; Pancreas

Indexed keywords

CLAUDIN 18; KI 67 ANTIGEN; MUCIN 2; PROTEIN P53; TRANSCRIPTION FACTOR GLI1;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CELL DIFFERENTIATION; CLINICAL ARTICLE; COMPARATIVE STUDY; DISEASE ASSOCIATION; EPITHELIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE; INTRADUCTAL CARCINOMA; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MUCINOUS CARCINOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; STAINING; STOMACH EPITHELIUM;

ADENOCARCINOMA, MUCINOUS; CARCINOMA IN SITU; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINES; MEMBRANE PROTEINS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 77955795081     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Hruban R, Maitra A, Kern SE and Goggins M: Precursor to pancreatic cancer. Gastroenterol Clin North Am 36: 831-856, 2007.
2. Sanada Y, Kunita S, and Yoshida K: Comparison between histologic subtype and growth pattern in intraductal papillary-mucinous carcinoma of the pancreas. Oncol Rep 19: 1435-1443, 2008.
3. Yonezawa S, Higashi M, Yamada N, Yokoyama S and Goto M: Significance of mucin expression in pancreatobiliary neoplasms. J Hepatobiliary Pancreat Surg 17: 108-124, 2010.
4. Ban S, Naithoh Y, Mino-Kenudson M, Sakurai T, Kuroda M, Koyama I, Lauwers GY, and Shimizu M. Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas: Its histopathologic difference between 2 major types. Am J Surg Pathol 30: 1561-1569, 2006. (Pubitemid 44808792)
5. Prasad NB, Biankin AV, Fukushima N, Maitra A, Dhara S, Elkahloun AG, Hruban RH, Goggins M and Leach SD: Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res 65: 1619-1629, 2005.
6. Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, and Tsutani Y: Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2. Pancreas 32: 164-170, 2006.
7. Sanada Y, Osada S, Tanaka Y, Tokuyama Y and Yoshida K: A case report of intraductal papillary-mucinous neoplasm of the pancreas showing morphologic transformation during follow-up periods. J Oncol 373465: 1-6, 2009.
8. Longnecker DS, Adler G and Hruban RH: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Intraductal papillary-mucinous neoplasms of the pancreas. In: Hamilton SR and Aaltonen LA (ed.). IARC Press: Lyon, France, pp. 237-240, 2000.
9. Furukawa T, Kloppel G, Adsay NV, Albores-Saavedra J, Fukushima N, Horii A, Hruban RN, Kato Y, Klimstra DS, Longnecker DS, Luttges J, Offerhaus GJA, Shimizu M, Sunamura M, Suriawinata A, Takaori K and Yonezawa S: Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 447: 794-799, 2005.
10. Karanjawala ZE, IIIlei PB, Ashfaq R, Infante JR, Murphy K, Pandey A, Schlich R, Winter J, Sharma R, Maitra A, Goggins M and Hruban RH: New markers of pancreatic cancer identified through differential gene expression analyses: Claudin-18 and Annexin A8. Am J Surg Pathol 32: 188-196, 2008.
11. Jeong S, Lee DH, Lee IL, Kwon KS, Kim PS, Kim HG, Shin YW, Kim YS and Kim YB: Expression of Ki-67, p53, and K-ras in chronic pancreatitis and pancreatic ductal adenocarcinoma. World J gastroenterol 11: 665-669, 2005.
12. Hruban R, Maitra A, and Goggins M: Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol 1: 306-316, 2008.
13. Real FX, Cibrian-Uhakte E and Martinelli P: Pancreatic cancer development and progression: remodeling the model. Gastroenterology 135: 24-28, 2008.
14. Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szant AJ, Goodrow T, Wood M, Obara T, Heath CY and Lynch H: Molecular pathology of primary and metastatic ductal pancreatic lesions: analysis of mutations and expression of the p53, MDM-2, and p21WAF1 genes in sporadic and familial lesions. Cancer 79: 700-719, 1997.
15. Embuscado EE, Laheru D, Ricci F, Yun KJ, de Boom Witzel S, Seigel A, Frickinger K, Hidalgo M, Bova GS and lacobuzio-Donahue CA: Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther 4: 548-554, 2005.
16. Gansauge F, Gansauge S, Schmidt E, Muller J and Beger HG: Prognostic significance of molecular alterations in human pancreatic carcinoma-an immunohistological study, Langenbeck Arch Surg 383: 152-155, 1998. (Pubitemid 28442529)
17. Sanada Y, Oue N, Mitani Y, Yoshida K, Nakayama H and Yasui W: Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol 208: 633-642, 2006.
18. Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, Huber C and Tureci O: Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14: 7624-7634, 2008.